[Federal Register Volume 65, Number 106 (Thursday, June 1, 2000)]
[Notices]
[Page 35107]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-13732]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: ``Antitumor Macrocyclic 
Lactones, Compositions and Methods of Use'' and ``Vacuolar-Type (H+)-
ATPase-Inhibiting Compounds, Compositions, and Uses Thereof''

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. Sec. 209 (c) (1) 
and 37 CFR Sec. 404.7 (a) (1) (i), that the National Institutes of 
Health, Department of Health and Human Services, is contemplating the 
grant of an exclusive license to practice the inventions embodied in 
U.S. Patent Application 60/053,784 entitled, ``Antitumor Macrocyclic 
Lactones, Compositions and Methods of Use'' filed on July 25, 1997; 
U.S. Patent Application 60/122,953 and 60/169,564 entitled, ``Vacuolar-
Type (H+)-ATPase-Inhibiting Compounds, Compositions, and Uses Thereof'' 
filed on March 5, 1999 and December 8, 1999 respectively to BioChem 
Pharma Inc. of Quebec, Canada. The patent rights in these inventions 
have been assigned to the United States of America.
    The prospective exclusive license territory will be worldwide and 
the field of use may be limited to composition of antitumor macrocyclic 
lactones and their uses as cancer therapeutic in humans.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before July 31, 
2000 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and 
other materials relating to the contemplated exclusive license should 
be directed to: Girish C. Barua, Ph.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD. 20852-3804. 
Telephone: (301) 496-7056, ext. 263; Facsimile (301) 402-0220; E-mail 
<a href="/cdn-cgi/l/email-protection#e0a281929581a7a08f84ce8e8988ce878f96"><span class="__cf_email__" data-cfemail="a6e4c7d4d3c7e1e6c9c288c8cfce88c1c9d0">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: The U.S. Patent Application 60/053,784 
claims a series of macrocyclic lactones based on compounds isolated 
from certain sponges and tunicates collected from Western Australia. 
The U.S. Patent Applications 60/122,953 and 60/169,564 describe 
inventions relating to vacuolar-type (H+)-ATPase-inhibitory activity of 
macrocyclic lactones. Vacuolar-type ATPases (V-ATPases) have been 
described as a universal proton pump which are important for a myriad 
of physiological functions such as sorting of membrane and organellar 
proteins; proinsulin conversion; neurotransmitter uptake, receptor 
recycling, and cellular degradative processes. Licensee of these 
inventions will be required to comport with all applicable federal and 
country-of-collection policies relating to biodiversity.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. Sec. 209 and 37 CFR 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establish that the grant of 
the license would not be consistent with the requirements of 35 U.S.C. 
Sec. 209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. Sec. 552.

    Dated: May 23, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 00-13732 Filed 5-31-00; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>